Tekla Price To Sales Ratio from 2010 to 2025
| HQH Stock | USD 17.21 0.17 0.98% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 77.69196045 | Current Value 73.81 | Quarterly Volatility 194.35016852 |
Check Tekla Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Healthcare's main balance sheet or income statement drivers, such as Depreciation And Amortization of 188.3 K, Interest Expense of 0.0 or Selling General Administrative of 13.2 M, as well as many indicators such as Price To Sales Ratio of 73.81, Dividend Yield of 0.0222 or PTB Ratio of 1.0. Tekla financial statements analysis is a perfect complement when working with Tekla Healthcare Valuation or Volatility modules.
Tekla | Price To Sales Ratio |
Latest Tekla Healthcare's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Tekla Healthcare Investors over the last few years. Price to Sales Ratio is figured by comparing Tekla Healthcare Inv stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Tekla Healthcare sales, a figure that is much harder to manipulate than other Tekla Healthcare Investors multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Tekla Healthcare's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Healthcare's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 84.13 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Tekla Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 254.40 | |
| Geometric Mean | 192.42 | |
| Coefficient Of Variation | 76.40 | |
| Mean Deviation | 169.91 | |
| Median | 166.55 | |
| Standard Deviation | 194.35 | |
| Sample Variance | 37,772 | |
| Range | 452 | |
| R-Value | (0.89) | |
| Mean Square Error | 8,285 | |
| R-Squared | 0.80 | |
| Slope | (36.40) | |
| Total Sum of Squares | 566,580 |
Tekla Price To Sales Ratio History
About Tekla Healthcare Financial Statements
Investors use fundamental indicators, such as Tekla Healthcare's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Tekla Healthcare's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 77.69 | 73.81 |
Currently Active Assets on Macroaxis
When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:Check out the analysis of Tekla Healthcare Correlation against competitors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.145 | Dividend Share 2.04 | Earnings Share 3.5 | Revenue Per Share | Quarterly Revenue Growth 0.172 |
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.